Rheumatoid arthritis

Views & Analysis

Breaking policy and perceptual barriers: Biosimilars

Experts from Research Partnership analyse the company’s Therapy Watch data to identify how market access policy has impacted the adoption of biosimilars.

News

ICER says 'marginal' benefits for AbbVie's new RA drug

AbbVie’s Rinvoq rheumatoid arthritis drug is an important part of the company’s strategy to replace lost sales as its mega-blockbuster Humira finally succumbs to cheaper biosimilar competit

Views & Analysis

Celltrion gears up for subcutaneous infliximab launch in Eur...

Celltrion Healthcare’s subcutaneous (SC) formulation of its infliximab biosimilar, codenamed CT-P13 SC, looks set to launch in Europe in the coming months in rheumatoid arthritis, after a p

Views & Analysis

Improving medicines adherence with VR

With medicine adherence still a major problem for pharma and healthcare systems, a collaboration between Cognitant Group and Addenbrooke’s Hospital –supported by grants from UCB and Pfizer

Partner Content

North American Prefilled Syringes Market to achieve 10% CAGR...

Prefilled Syringes Market to cross $9.7bn by 2025

News

Gilead invests $5.1bn in Belgian biotech Galapagos

Belgian biotech Galapagos has signed a shiny new deal with Gilead to develop inflammatory disease and rheumatoid arthritis drugs, where the big US pharma will pay $3.95 billion up front and

Breaking policy and perceptual barriers: Biosimilars

ICER says 'marginal' benefits for AbbVie's new RA drug

Celltrion gears up for subcutaneous infliximab launch in Eur...

Improving medicines adherence with VR

North American Prefilled Syringes Market to achieve 10% CAGR...

Gilead invests $5.1bn in Belgian biotech Galapagos

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

Rheumatoid arthritis

Editor's Picks